.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,185,351

« Back to Dashboard

Claims for Patent: 5,185,351

Title: Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
Abstract:Angiotensin II receptor antagonists having the formula: ##STR1## which are useful in regulating hypertension and in the treatment of congestive heart failure, renal failure, and glaucoma, pharmaceutical compositions including these antagonists, and methods of using these compounds to produce angiotensin II receptor antagonism in mammals.
Inventor(s): Finkelstein; Joseph A. (Philadelphia, PA), Keenan; Richard M. (Malvern, PA), Weinstock; Joseph (Phoenixville, PA)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:07/746,262
Patent Claims: 1. A compound of the formula: ##STR26## in which: R.sup.1 is adamantyl, phenyl, biphenyl, or naphthyl, with each aryl group being unsubstituted or substituted by one to three substituents selected from Cl, Br, F, I, C.sub.1 -C.sub.6 alkyl, nitro, A--CO.sub.2 R.sup.7, tetrazol-5-yl, C.sub.1 -C.sub.6 alkoxy, hydroxy, SC.sub.1 -C.sub.6 alkyl, SO.sub.2 NHR.sup.7, NHSO.sub.2 R.sup.7, SO.sub.3 H, CONR.sup.7 R.sup.7, CN, SO.sub.2 C.sub.1 -C.sub.6 alkyl, NHSO.sub.2 R.sup.7, PO(OR.sup.7).sub.2, NR.sup.7 R.sup.7, NR.sup.7 COH, NR.sup.7 COC.sub.1 -C.sub.6 -alkyl, NR.sup.7 CON(R.sup.7).sub.2, NR.sup.7 COW, W, SO.sub.2 W;

m is 0-4;

R.sup.2 is C.sub.2 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, C.sub.3 -C.sub.10 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, or (CH.sub.2).sub.0-8 phenyl unsubstituted or substituted by one to three substituents selected from C.sub.1 -C.sub.6 alkyl, nitro, Cl, Br, F, I, hydroxy, C.sub.1 -C.sub.6 alkoxy, NR.sup.7 R.sup.7, CO.sub.2 R.sup.7, CN, CONR.sup.7 R.sup.7, W, tetrazol-5-yl, NR.sup.7 COC.sub.1 -C.sub.6 alkyl, NR.sup.7 COW, SC.sub.1 -C.sub.6 alkyl, SO.sub.2 W, or SO.sub.2 C.sub.1 -C.sub.6 alkyl;

X is a single bond, S, NR.sup.7, or O;

R.sup.3 is hydrogen, Cl, Br, F, I, CHO, hydroxymethyl, COOR.sup.7, CONR.sup.7 R.sup.7, NO.sub.2, W, CN, NR.sup.7 R.sup.7, or phenyl;

R.sup.4 and R.sup.5 are independently hydrogen, C.sub.1 -C.sub.6 alkyl, thienyl--Y--, furyl--Y--, pyrazolyl--Y--, imidazolyl--Y--, pyrrolyl--Y--, triazolyl--Y--, oxazolyl--Y--, isoxazolyl--Y--, thiazolyl--Y--, pyridyl--Y--, or tetrazolyl--Y--, except that R.sup.4 and R.sup.5 are not both selected from hydrogen and C.sub.1 -C.sub.6 alkyl and each heterocyclic ring is unsubstituted or substituted by C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, Cl, Br, F, I, NR.sup.7 R.sup.7, CO.sub.2 R.sup.7, SO.sub.2 NHR.sup.7, SO.sub.3 H, or CONR.sup.7 R.sup.7, OH, NO.sub.2, W, SO.sub.2 W, SC.sub.1 -C.sub.6 alkyl, SO.sub.2 C.sub.1 -C.sub.6 alkyl, NR.sup.7 COH, NR.sup.7 COW, or NR.sup.7 COC.sub.1 -C.sub.6 alkyl;

Y is a single bond, O, S, or C.sub.1 -C.sub.6 alkyl which is straight or branched or optionally substituted by phenyl or benzyl, wherein each of the aryl groups is unsubstituted or substituted by halo, NO.sub.2, CF.sub.3, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, CN, or CO.sub.2 R.sup.7 ;

R.sup.6 is --Z--COOR.sup.8 or --Z--CONR.sup.7 R.sup.7 ;

Z is a single bond, vinyl, --CH.sub.2 --O--CH.sub.2 --, methylene optionally substituted by C.sub.1 -C.sub.6 alkyl, one or two benzyl groups, thienylmethyl, or furylmethyl, or --C(O)NHCHR.sup.9 --, wherein R.sup.9 is H, C.sub.1 -C.sub.6 alkyl, phenyl, benzyl, thienylmethyl, or furylmethyl;

W is C.sub.n F.sub.2n+1, wherein n is 1-3;

A is --(CH.sub.2).sub.m --, --CH.dbd.CH--, --O(CH.sub.2).sub.n --, or --S(CH.sub.2).sub.n --;

each R.sup.7 independently is hydrogen, C.sub.1 -C.sub.6 alkyl, or (CH.sub.2).sub.m phenyl; and

R.sup.8 is hydrogen, C.sub.1 -C.sub.6 alkyl, or 2-di(C.sub.1 -C.sub.6 alkyl)-amino-2-oxoethyl; or a pharmaceutically acceptable salt thereof.

2. A compound of claim 1 in which one of R.sup.4 and R.sup.5 is hydrogen or C.sub.1 -C.sub.4 alkyl.

3. A compound of claim 2 in which R.sup.1 is phenyl or naphthyl, with each aryl group being unsubstituted or substituted by one to three substituents selected from chloro, fluoro, trifluoromethyl, nitro, methyl, methoxy, hydroxy, sulfamyl, cyano, carboxy, --(CH.sub.2).sub.1-2 carboxy, --CH.dbd.CH--carboxy, --OCH.sub.2 -carboxy, carboC.sub.1 -C.sub.6 alkoxy, carbamoyl, or tetrazol-5-yl, and m is 0-2.

4. A compound of claim 3 in which X is a single bond or S and R.sup.2 is C.sub.2 -C.sub.8 alkyl.

5. A compound of claim 4 in which R.sup.3 is hydrogen, chloro, fluoro, or trifluoromethyl and R.sup.4 is hydrogen or C.sub.1 -C.sub.4 alkyl.

6. A compound of claim 5 in which R.sup.6 is COOH, COOC.sub.1-2 alkyl or CONH.sub.2.

7. A compound of claim 6 in which R.sup.5 is thienylmethyl, thienylethyl, furylmethyl, imidazolylmethyl, or pyridylmethyl, each of which is optionally substituted by methyl or methoxy.

8. A compound of claim 7 which is the E isomer, wherein the R.sup.6 group and the imidazole are trans to each other.

9. A compound of claim 8 which is (E)-3-[2-n-butyl-1-{(2-chlorophenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl )methyl-2-propenoic acid or a pharmaceutically acceptable salt thereof.

10. A compound of claim 8 which is (E)-3-[2-n-butyl-1-{(4-carboxy-2-chlorophenyl)methyl}-1H-imidazol-5-yl]-2- (2-thienyl)methyl-2-propenoic acid or a pharmaceutically acceptable salt thereof.

11. A compound of claim 8 which is (E)-3-[2-n-butyl-1-{(4-carboxy-3-chlorophenyl)methyl}-1H-imidazol-5-yl]-2- (2-thienyl)methyl-2-propenoic acid or a pharmaceutically acceptable salt thereof.

12. A compound of claim 8 which is (E)-3-[2-n-propyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thien yl)methyl-2-propenoic acid or a pharmaceutically acceptable salt thereof.

13. A compound of claim 8 which is (E)-3-[2-n-hexyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thieny l)methyl-2-propenoic acid or a pharmaceutically acceptable salt thereof.

14. A compound of claim 8 which is (E)-3-[2-n-butyl-1-{(4-carboxy-2,3-dichlorophenyl)methyl}-1H-imidazol-5-yl ]-2-propenoic acid or a pharmaceutically acceptable salt thereof.

15. A compound of claim 8 which is (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thieny l)methyl-2-propenoic acid or a pharmaceutically acceptable salt thereof.

16. A compound of claim 15 which is (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thieny l)methyl-2-propenoic acid methanesulfonate.

17. A compound of claim 8 which is:

(E)-3-[2-n-butyl-1-{(2-nitrophenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)m ethyl-2-propenoic acid

(E)-3-[2-n-butyl-1-{(2-chlorophenyl)methyl}-1H-imidazol-5-yl]-2-(2-furyl)me thyl-2-propenoic acid

(E)-3-[2-n-butyl-1-{(4-carbomethoxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-th ienyl)methyl-2-propenoic acid

(E)-3-[2-n-butyl-1-{(2-chlorophenyl)methyl}-1H-imidazol-5-yl]-2-(4-imidazol yl)methyl-2-propenoic acid;

(E)-3-[2-n-butyl-1-{(2-chlorophenyl)methyl}-1H-imidazol-5-yl]-2-(3-thienyl) methyl-2-propenoic acid;

(E)-3-[2-n-butyl-1-{(2-chlorophenyl)methyl}-1H-imidazol-5-yl]-2-(5-methyl-2 -thienyl)methyl-2-propenoic acid;

(E)-3-[2-n-butyl-1-{(2-cyanophenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)m ethyl-2-propenoic acid;

(E)-3-[2-n-butyl-1-{(4-methoxy-3-methylphenyl)methyl}-1H-imidazol-5-yl]-2-( 2-thienyl)methyl-2-propenoic acid;

(E)-3-[2-n-butyl-1-{(2-chlorophenyl)methyl}-1H-imidazol-5-yl]-2-(4-pyridyl) methyl-2-propenoic acid;

(E)-3-[2-n-butyl-1-{(2-chlorophenyl)methyl}-1H-imidazol-5-yl]-2-(5-methoxy- 2-thienyl)methyl-2-propenoic acid;

(E)-3-[2-butyl-1-{(2,3-dichlorophenyl)methyl}-1H-imidazol-5-yl]-2-(2-thieny l)methyl-2-propenoic acid;

(E)-3-[2-n-butyl-1-{(3,4-dicarboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thi enyl)methyl-2-propenoic acid;

(E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl )ethyl-2-propenoic acid;

(E)-3-[2-n-butyl-1-{(4-carboxymethylphenyl)methyl}-1H-imidazol-5-yl]-2-(2-t hienyl)methyl-2-propenoic acid;

(E)-3-[2-n-butyl-1-{(4-carboxy-3-hydroxyphenyl)methyl}1H-imidazol-5-yl]-2-( 2-thienyl)methyl-2-propenoic acid; or

(E)-3-[2-n-butyl-1-{(2-trifluoromethylphenyl)methyl}-1H-imidazol-5-yl]-2-(2 -thienyl)methyl-2-propenoic acid; or a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition comprising a pharmaceutical carrier and a compound of claim 1.

19. A pharmaceutical composition of claim 18 in which the compound is (E)-3-[2-n-butyl-1-{(2-chlorophenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl )methyl-2-propenoic acid.

20. A pharmaceutical composition of claim 18 in which the compound is (E)-3-[2-n-butyl-1-{(4-carboxy-2-chlorophenyl)methyl}-1H-imidazol-5-yl]-2- (2-thienyl)methyl-2-propenoic acid.

21. A pharmaceutical composition of claim 18 in which the compound is (E)-3-[2-n-butyl-1-{(4-carboxy-3-chlorophenyl)methyl}-1H-imidazol-5-yl]-2- (2-thienyl)methyl-2-propenoic acid.

22. A pharmaceutical composition of claim 18 in which the compound is (E)-3-[2-n-propyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thien yl)methyl-2-propenoic acid.

23. A pharmaceutical composition of claim 18 in which the compound is (E)-3-[2-n-hexyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thieny l)methyl-2-propenoic acid.

24. A pharmaceutical composition of claim 18 in which the compound is (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thieny l)methyl-2-propenoic acid.

25. A pharmaceutical composition of claim 18 in which the compound is (E)-3-[2-n-butyl-1-{(4-carboxy-2,3-dichlorophenyl)methyl}-1H-imidazol-5-yl ]-2-propenoic acid.

26. A pharmaceutical composition of claim 18 in which the compound is (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thieny l)methyl-2-propenoic acid methanesulfonate.

27. A pharmaceutical composition of claim 18 in which the compound is:

(E)-3-[2-n-butyl-1-{(2-chlorophenyl)methyl}-1H-imidazol-5-yl]-2-(2-furyl)me thyl-2-propenoic acid

(E)-3-[2-n-butyl-1-{(2-nitro-phenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl) -methyl-2-propenoic acid

(E)-3-[2-n-butyl-1-{(4-carbomethoxy-phenyl)methyl}-1H-imidazol-5-yl]-2-(2-t hienyl)-methyl-2-propenoic acid

(E)-3-[2-n-butyl-1-{(2-chlorophenyl)methyl}-1H-imidazol-5-yl]-2-(4-imidazoy l)methyl-2-propenoic acid;

(E)-3-[2-n-butyl-1-{(2-chlorophenyl)methyl}-1H-imidazol-5-yl]-2-(3-thienyl) methyl-2-propenoic acid;

(E)-3-[2-n-butyl-1-{(2-chlorophenyl)methyl}-1H-imidazol-5-yl]-2-(5-methyl-2 -thienyl)methyl-2-propenoic acid;

(E)-3-[2-n-butyl-1-{(2-cyanophenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)m ethyl-2-propenoic acid;

(E)-3-[2-n-butyl-1-{(4-methoxy-3-methylphenyl)-methyl}-1H-imidazol-5-yl]-2- (2-thienyl)methyl-2-propenoic acid;

(E)-3-[2-n-butyl-1-{(2-chlorophenyl)methyl}-1H-imidazol-5-yl[-2-(4-pyridyl) methyl-2-propenoic acid;

(E)-3-[2-n-butyl-1-(2-chlorophenyl)methyl}-1H-imidazol-5-yl]-2-(5-methoxy-2 -thienyl)methyl-2-propenoic acid;

(E)-3-[2-n-butyl-1-{(2,3-dichlorophenyl)-methyl}-1H-imidazol-5-yl]-2-(2-thi enyl)methyl-2-propenoic acid;

(E)-3-[2-n-butyl-1-{(2-trifluoromethylphenyl)-methyl}-1H-imidazol-5-yl]-2-( 2-thienyl)methyl-2-propenoic acid

(E)-3-[2-n-butyl-1-{(3,4-dicarboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thi enyl)methyl-2-propenoic acid;

(E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl )ethyl-2-propenoic acid;

(E)-3-[2-n-butyl-1-{(4-carboxymethylphenyl)methyl}-1H-imidazol-5-yl]-2-(2-t hienyl)methyl-2-propenoic acid; or

(E)-3-[2-n-butyl-1-{(4-carboxy-3-hydroxyphenyl)methyl}1H-imidazol-5-yl]-2-( 2-thienyl)methyl-2-propenoic acid.

28. A method of antagonizing angiotensin II receptors which comprises administering to a subject in need thereof an effective amount of a compound of claim 1.

29. A method of treating hypertension which comprises administering to a subject in need thereof an effective amount of a compound of claim 1.

30. A method of treating congestive heart failure which comprises administering to a subject in need thereof an effective amount of a compound of claim 1.

31. A method of treating renal failure which comprises administering to a subject in need thereof an effective amount of a compound of claim 1.

32. A method of treating glaucoma which comprises administering to a subject in need thereof an effective amount of a compound of claim 1.

33. The method of claim 28 wherein the compound is (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl-2-propanoic acid.

34. The method of claim 28 wherein the compound is (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl-2-propanoic acid methanesulfonate.

35. The method of claim 29 wherein the compound is (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl-2-propanoic acid.

36. The method of claim 29 wherein the compound is (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl-2-propanoic acid methanesulfonate.

37. The method of claim 30 wherein the compound is (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl-2-propanoic acid.

38. The method of claim 30 wherein the compound is (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl-2-propanoic acid methanesulfonate.

39. The method of claim 31 wherein the compound is (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl-2-propanoic acid.

40. The method of claim 31 wherein the compound is (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl-2-propanoic acid methanesulfonate.

41. The method of claim 32 wherein the compound is (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl-2-propanoic acid.

42. The method of claim 32 wherein the compound is (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl-2-propanoic acid methanesulfonate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc